Effects of Tofacitinib vs Methotrexate on Rheumatoid Arthritis Interstitial Lung Disease (PULMORA)
Effects of Tofacitinib vs Methotrexate on Clinical and Molecular Disease Activity Markers in Joints and Lungs in Early Rheumatoid Arthritis (PULMORA) - A Randomized, Controlled, Open-label, Assessor-blinded, Phase IV Trial
Sponsor: Göteborg University
Terminated
Low recruitment due to the pandemic and high screening failure rate in particular because of low prevalence of interstitial abnormalities at diagnosis in Sweden.
This PHASE4 trial investigates ILD and Interstitial Lung Disease Due to Systemic Disease (Disorder) and is currently terminated or withdrawn. Göteborg University leads this study, which shows 10 recorded versions since 2020 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Jun 2024 — Jul 2024 [monthly]
Terminated PHASE4
Status: Recruiting → Terminated
-
May 2022 — Jun 2024 [monthly]
Recruiting PHASE4
▶ Show 5 earlier versions
-
Mar 2021 — May 2022 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Jan 2021 — Mar 2021 [monthly]
Not Yet Recruiting PHASE4
-
Nov 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE4
-
May 2020 — Nov 2020 [monthly]
Not Yet Recruiting PHASE4
-
Apr 2020 — May 2020 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Göteborg University
- Vastra Gotaland Region
For direct contact, visit the study record on ClinicalTrials.gov .